Phosphate binder regimens, by DOPPS country and cross-section

  Ca-based only Sevelamer only Ca + sev. only La-based only Other combin. None
N Ptnts Wgtd % N Ptnts Wgtd % N Ptnts Wgtd % N Ptnts Wgtd % N Ptnts Wgtd % N Ptnts Wgtd %
DOPPS Country DOPPS Cross-section 5,313 58.3% 975 10.6% 422 4.6% . . 644 7.1% 1,763 19.4%
All DOPPS 2(2002)
DOPPS 3(2006) 3,694 43.1% 1,807 21.0% 870 10.2% 92 1.2% 750 8.7% 1,339 15.7%
DOPPS 3(2007) 2,985 38.7% 1,459 18.8% 1,045 13.5% 125 1.7% 827 10.8% 1,231 16.4%
AusNZ DOPPS 2(2002) 320 63.5% 2 0.3% . . . . 130 25.2% 61 11.1%
DOPPS 3(2006) 291 55.7% 1 0.2% . . . . 173 32.3% 62 11.8%
DOPPS 3(2007) 251 52.3% 3 0.6% 1 0.2% . . 185 37.7% 46 9.2%
Belgium DOPPS 2(2002) 445 82.9% 1 0.2% 5 0.8% . . 27 4.8% 60 11.3%
DOPPS 3(2006) 265 52.1% 85 16.6% 67 12.2% . . 11 2.1% 81 16.9%
DOPPS 3(2007) 170 42.0% 53 12.3% 115 26.4% . . 8 1.5% 74 17.8%
Canada DOPPS 2(2002) 457 76.5% 31 4.9% 36 5.9% . . 19 3.5% 58 9.1%
DOPPS 3(2006) 348 63.9% 62 11.0% 71 13.0% . . 20 3.3% 50 8.8%
DOPPS 3(2007) 242 53.5% 48 10.2% 86 19.3% . . 33 7.6% 36 9.5%
France DOPPS 2(2002) 275 51.6% 52 9.8% 46 9.0% . . 26 5.0% 129 24.6%
DOPPS 3(2006) 164 30.2% 156 28.1% 89 16.2% . . 28 5.1% 114 20.4%
DOPPS 3(2007) 158 29.1% 107 19.8% 122 21.6% 18 3.1% 43 7.8% 95 18.6%
Germany DOPPS 2(2002) 260 46.3% 29 5.1% 6 1.1% . . 127 21.9% 149 25.6%
DOPPS 3(2006) 276 48.1% 62 10.4% 20 3.4% 1 0.2% 119 20.1% 105 17.9%
DOPPS 3(2007) 257 40.7% 48 7.5% 43 7.1% 5 0.7% 169 26.8% 101 17.2%
Italy DOPPS 2(2002) 150 25.9% 152 26.3% 51 8.8% . . 90 15.7% 133 23.3%
DOPPS 3(2006) 91 17.1% 205 38.4% 42 7.9% 1 0.2% 70 13.0% 124 23.4%
DOPPS 3(2007) 107 19.5% 210 38.7% 50 8.8% . . 71 13.0% 104 19.9%
Japan DOPPS 2(2002) 1,363 75.5% . . . . . . 19 1.0% 423 23.5%
DOPPS 3(2006) 1,022 55.6% 292 15.7% 225 12.4% . . 23 1.3% 270 14.9%
DOPPS 3(2007) 928 49.5% 278 14.8% 286 15.5% . . 28 1.5% 347 18.7%
Spain DOPPS 2(2002) 311 50.6% 50 8.1% 63 10.3% . . 129 21.0% 60 10.0%
DOPPS 3(2006) 171 25.8% 211 31.8% 102 15.2% 4 0.6% 85 12.5% 93 14.0%
DOPPS 3(2007) 135 25.0% 143 25.6% 109 19.0% 2 0.3% 71 12.8% 95 17.3%
Sweden DOPPS 2(2002) 279 50.7% 75 14.0% 66 12.1% . . 13 2.4% 114 20.8%
DOPPS 3(2006) 170 31.3% 143 26.3% 71 13.1% 2 0.5% 78 14.1% 78 14.6%
DOPPS 3(2007) 116 22.7% 120 24.4% 81 15.7% 28 5.4% 108 20.5% 58 11.4%
UK DOPPS 2(2002) 234 41.3% 63 10.7% 16 2.9% . . 46 8.2% 206 37.0%
DOPPS 3(2006) 172 38.5% 103 22.7% 34 8.2% 8 1.7% 25 5.4% 103 23.6%
DOPPS 3(2007) 141 40.8% 70 18.7% 31 9.1% 7 1.4% 23 6.6% 79 23.4%
US DOPPS 2(2002) 1,219 53.9% 520 22.9% 133 5.8% . . 18 0.8% 370 16.5%
DOPPS 3(2006) 724 39.0% 487 27.1% 149 8.5% 76 4.7% 118 6.7% 259 14.1%
DOPPS 3(2007) 480 35.1% 379 27.8% 121 9.7% 65 5.5% 88 6.7% 196 15.2%

Medications reported as prescribed (not necessarily taken) in previous four months, among all patients. OTHER COMBIN. includes all mono- or combination therapies not otherwise listed.

Please see additional methodological information in the Data Sources and Methods section.